Skip to main content
David Kandzari, MD, Cardiology, Atlanta, GA

David E Kandzari MD

Cardiology•Atlanta, GA

Adult Congenital Heart Disease, Interventional Cardiology

Physician

Join to view full profile

  • 95 Collier Rd NWSte 2065Atlanta, GA 30309

  • Phone+1 404-605-2800

  • Fax+1 404-720-0911

Dr. Kandzari is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Kandzari's full profileAlready have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Cardiovascular Disease, 1998 - 2002
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1995 - 1998
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1995

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2008 - Present
  • GA State Medical License
    GA State Medical License 2010 - 2028
  • TX State Medical License
    TX State Medical License 2008 - 2011
  • NC State Medical License
    NC State Medical License 1999 - 2008
  • VA State Medical License
    VA State Medical License 2004 - 2006
  • Interventional Cardiology
    American Board of Internal Medicine Interventional Cardiology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
  • CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012, 2014-2017
  • CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Original Investigations Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents: BIOFLOW V 2-Year Results  
    David E Kandzari, Ron Waksman, Donald E Cutlip, Elie G Gharib, ScienceDirect
  • Original Investigation Left Main Revascularization with PCI or CABG in Patients with Chronic Kidney Disease: EXCEL Trial  
    John D Puskas, David E Kandzari, Gennaro Giustino, Roxana Mehran, Martin B Leon, Philippe Genereux, Michael 3rd Ragosta, Charles A Simonton, Irving L Kron, Gregg W Stone, ScienceDirect
  • Focus on Left Main Interventions Outcomes After Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting According to Lesion Site: Results f...  
    Gregg W Stone, David E Kandzari, Nicholas J Lembo, ScienceDirect

Lectures

  • Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization 3-Year Outcomes from the ... 
    Society for Cardiovascular Angiography and Interventions, Phoenix, Arizona - 1/19/2013
  • The Target BP Program: Ongoing and Future Studies 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/27/2019
  • Choose Carefully: The Best New Generation DES are Associated With Meaningful Improvements In Performance and Outcomes! 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019

Authored Content

  • Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization 3-Year Outcomes from the Randomized BIOFLOW V TrialJune 2020
  • Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization 3-Year Outcomes from the Randomized BIOFLOW V TrialJune 2020
  • The Day After a Primary EndpointMarch 2018

Press Mentions

  • Piedmont Augusta Hospital Performs First Renal Denervation Procedure to Treat Resistant Hypertension
    Piedmont Augusta Hospital Performs First Renal Denervation Procedure to Treat Resistant HypertensionNovember 19th, 2025
  • Three-Year SPYRAL HTN-ON MED Results Show Sustained, 18 mmHg Office-Based Blood Pressure Reductions
    Three-Year SPYRAL HTN-ON MED Results Show Sustained, 18 mmHg Office-Based Blood Pressure ReductionsOctober 26th, 2025
  • Long-Term SPYRAL HTN-ON MED Data Presented for Medtronic’s Symplicity Spyral RDN System
    Long-Term SPYRAL HTN-ON MED Data Presented for Medtronic’s Symplicity Spyral RDN SystemOctober 26th, 2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. David Kandzari, Dr. David Kandzari, MD, Dr. D Kandzari, Dr. David E Kandzari